PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
7.01%
Net income growth under 50% of RVPH's 23.56%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
8.54%
D&A growth of 8.54% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
100.00%
Deferred tax of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
48.65%
SBC growth while RVPH is negative at -5.51%. John Neff would see competitor possibly controlling share issuance more tightly.
-142.09%
Both reduce yoy usage, with RVPH at -902.32%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-124.49%
Negative yoy AP while RVPH is 230.93%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-84.29%
Both reduce yoy usage, with RVPH at -411.07%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
47.93%
Some yoy increase while RVPH is negative at -583.35%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
1.55%
Some CFO growth while RVPH is negative at -32.10%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut debt repayment yoy while RVPH is 249.21%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1131.77%
We slightly raise equity while RVPH is negative at -100.00%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.